The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review

Journal of Clinical Lipidology

Volumn 4, Issue 6, 2010, Pages 462-471

  Simpson Jr , Ross J ^a   Mendys, Philip ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Adherence; Cardiovascular diseases; Drugs; Lipids; Morbidity; Prevention

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRATE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW; THERAPY EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 78649678941     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.08.026     Document Type: Review

References (33)

1. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
2. L. Osterberg, and T. Blaschke Adherence to medication N Engl J Med 353 2005 487 497
3. S. Perreault, L. Blais, and D. Lamarre Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention Br J Clin Pharmacol 59 2005 564 573
4. S. Perreault, L. Blais, and A. Dragomir Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease Eur J Clin Pharmacol 61 2005 667 674
5. S.J. Kamal-Bahl, T. Burke, D. Watson, and C. Wentworth Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice Am J Cardiol 99 2007 530 534
6. C.A. Jackevicius, M. Mamdani, and J.V. Tu Adherence with statin therapy in elderly patients with and without acute coronary syndromes JAMA 288 2002 462 467
7. N.D. Shah, S.M. Dunlay, and H.H. Ting Long-term medication adherence after myocardial infarction: experience of a community Am J Med 122 2009 961.e7-e13
8. S.B. Cherry, J.S. Benner, M.A. Hussein, S.S. Tang, and M.B. Nichol The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients Value Health 12 2009 489 497
9. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study Eur Heart J 18 1997 1718 1724
10. M.H. Ebell, J. Siwek, and B.D. Weiss Simplifying the language of evidence to improve patient care: Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in medical literature J Fam Pract 53 2004 111 120
11. M.H. Bouchard, A. Dragomir, L. Blais, A. Berard, D. Pilon, and S. Perreault Impact of adherence to statins on coronary artery disease in primary prevention Br J Clin Pharmacol 63 2007 698 708
12. S. Perreault, A. Dragomir, and L. Blais Impact of better adherence to statin agents in the primary prevention of coronary artery disease Eur J Clin Pharmacol 65 2009 1013 1024
13. S. Perreault, L. Ellia, and A. Dragomir Effect of statin adherence on cerebrovascular disease in primary prevention Am J Med 122 2009 647 655
14. D.F. Blackburn, R.T. Dobson, J.L. Blackburn, and T.W. Wilson Cardiovascular morbidity associated with nonadherence to statin therapy Pharmacotherapy 25 2005 1035 1043
15. P.M. Ho, D.J. Magid, F.A. Masoudi, D.L. McClure, and J.S. Rumsfeld Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease BMC Cardiovasc Disord 6 2006 48
16. P.M. Ho, D.J. Magid, and S.M. Shetterly Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease Am Heart J 155 2008 772 779
17. I. Holme, M. Szarek, and N.B. Cater Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study Eur J Cardiovasc Prev Rehabil 16 2009 315 320
18. E. Lesaffre, D. Kocmanova, P.A. Lemos, C.M. Disco, and P.W. Serruys A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS Clin Ther 25 2003 2431 2447
19. J.N. Rasmussen, A. Chong, and D.A. Alter Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction JAMA 297 2007 177 186
20. L. Wei, J. Wang, P. Thompson, S. Wong, A.D. Struthers, and T.M. MacDonald Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study Heart 88 2002 229 233
21. L. Wei, T. Fahey, and T.M. MacDonald Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome Br J Clin Pharmacol 66 2008 110 116
22. T.B. Gibson, T.L. Mark, K. Axelsen, O. Baser, D.A. Rublee, and K.A. McGuigan Impact of statin copayments on adherence and medical care utilization and expenditures Am J Manag Care 2006 12 Spec no.:SP11-SP19
23. P.M. Ho, J.S. Rumsfeld, and F.A. Masoudi Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus Arch Intern Med 166 2006 1836 1841
24. N. Howell, R. Trotter, D.R. Mottram, and P.H. Rowe Compliance with statins in primary care Pharma J 272 2004 23 26
25. V. Shalev, G. Chodick, H. Silber, E. Kokia, J. Jan, and A.D. Heymann Continuation of statin treatment and all-cause mortality: a population-based cohort study Arch Intern Med 169 2009 260 268
26. F. Colivicchi, A. Bassi, M. Santini, and C. Caltagirone Discontinuation of statin therapy and clinical outcome after ischemic stroke Stroke 38 2007 2652 2657
27. J. Hippisley-Cox, and C. Coupland Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis Heart 92 2006 752 758
28. P.M. Ho, J.A. Spertus, and F.A. Masoudi Impact of medication therapy discontinuation on mortality after myocardial infarction Arch Intern Med 166 2006 1842 1847
29. F.J. Penning-van Beest, F. Termorshuizen, W.G. Goettsch, O.H. Klungel, J.J. Kastelein, and R.M. Herings Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study Eur Heart J 28 2007 154 159
30. C.R. Dormuth, A.R. Patrick, and W.H. Shrank Statin adherence and risk of accidents: a cautionary tale Circulation 119 2009 2051 2057
31. C.N. Bairey Merz, M.J. Alberts, and G.J. Balady ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease. A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to develop a competence and training statement on prevention of cardiovascular disease) Circulation 120 2009 100 126
32. R.O. Bonow, F.A. Masoudi, and J.S. Rumsfeld ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures J Am Coll Cardiol 52 2008 2113 2117
33. H.M. Krumholz, J.L. Anderson, and B.L. Bachelder ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction): developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine Circulation 118 2008 2596 2648